Alpine Immune Sciences

Modern therapies targeting the immune synapse

 

Alpine Immune Sciences

Novel proteins created using directed evolution-based discovery platform

 

Alpine Immune Sciences

Helping patients with cancer and autoimmune disease

1
1

Modern therapies targeting the immune synapse

We create modern, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory disorders, and other diseases.

Alpine Immune Sciences (AIS) was founded in 2015 by experts in the field of recombinant, protein-based immunotherapies. Alpine capitalizes on our unique understanding of the immune synapse, evolving native proteins for therapeutic benefit.

At Alpine Immune Sciences, we are applying our platform discovery technology to bring innovative new drugs to people living with cancer and autoimmune diseases

vIgDTM Platform

Alpine’s powerful vIgDTM (variant immunoglobulin domain) platform is based upon proteins native to the immune synapse. Alpine’s vIgDs can engage multiple targets simultaneously, are significantly more potent then native proteins, and have the potential improve therapeutic outcomes for the treatment of cancer, autoimmune/inflammatory conditions, or infectious diseases.

Because vIgDs are based upon natural participants in the immune synapse, they potentially provide a mechanistic advantage over larger, more artificial constructs.

TIPTM Program

Alpine’s TIPTM (transmembrane immunomodulatory protein) program potentially enhances Engineered Cellular Therapies (ECTs) like CAR-T, TCR, and TIL.

Researchers of ECTs use immune system cells from a patient or a donor, engineering these cells to treat patients. Early data from these programs show great promise, particularly in hematologic cancers.

Alpine’s TIPs are based upon our core vIgD™ technology. The primary difference is vIgDs are stand-alone drugs while TIPs are engineered to become part of ECTs to potentially increase specificity, persistence, and/or efficacy.